Danish biotechnology company designing and developing peptide-based medicines, mainly for metabolic diseases such as diabetes and obesity. Listed on Nasdaq Copenhagen since 2010.
相关临床试验
44
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1999
进行中（未招募）
3
6.8%
已完成
33
75.0%
招募中
5
11.4%
终止
2
4.5%
撤回
1
2.3%
暂无批准数据
- Royalty Pharma will provide $100 million to Zealand Pharma in exchange for its economic interests related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera. - Rusfertide mimics hepcidin to regulate iron homeostasis and red blood cell production, aiming to help patients achieve sustained hematocrit control via once-weekly subcutaneous self-injection. - The U.S. FDA has set a PDUFA goal date in the third quarter of 2026 for the rusfertide NDA, with Takeda responsible for global commercialization. - Zealand Pharma will redeploy the immediate capital toward growth opportunities under its Metabolic Frontier 2030 strategy.
- Zealand Pharma executed share repurchases totaling DKK 54.1 million during week 23 of its ongoing buy-back program, bringing total accumulated repurchases to DKK 240.9 million. - The company now holds approximately 2.27% of its total share capital as treasury shares following the latest transactions and a concurrent capital increase. - Zealand Pharma disclosed transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons, maintaining regulatory transparency. - The Danish biotech continues to advance its pipeline of peptide-based medicines for obesity and metabolic health, with three candidates in late-stage development.
- Roche has deployed over $15 billion in upfront capital across roughly two years to enter obesity, inflammatory bowel disease, allogeneic cell therapy, and neurodegeneration, marking a strategic pivot beyond its traditional oncology base. - The company's TL1A antibody afimkibart, acquired via the $7.1 billion Telavant deal, faces intensified competition after Merck's tulisokibart delivered the first positive phase 3 results in ulcerative colitis in June 2026. - Roche's obesity strategy centers on CT-388, a dual GLP-1/GIP agonist showing 22.5% placebo-adjusted weight loss at 48 weeks, combined with Zealand Pharma's amylin analog petrelintide in a $5.3 billion collaboration. - The Poseida Therapeutics acquisition provides Roche an allogeneic CAR-T platform, with lead candidate P-BCMA-ALLO1 demonstrating a 91% overall response rate in heavily pretreated multiple myeloma patients.
- Eli Lilly has licensed sonefpeglutide, a once-monthly GLP-2 analogue from Hanmi Pharma, for $75 million upfront plus up to $1.185 billion in milestone payments. - The drug is currently in Phase 2 trials for short bowel syndrome, a rare condition where patients cannot absorb sufficient nutrients from food. - Sonefpeglutide offers potential advantages over existing treatments with its monthly dosing schedule compared to Takeda's daily Gattex, the only approved GLP-2 agonist. - The licensing agreement covers worldwide rights excluding South Korea, with Lilly planning additional clinical trials beyond the ongoing short bowel syndrome study.
- N4 Pharma has appointed Dr. David H. Solomon as CEO to lead the company's strategic transformation from a technology platform provider to a developer of RNA-based therapeutics. - The company has filed a patent application for a novel siRNA therapy targeting cardiovascular risk reduction while pausing its ECP105 program to focus resources on RNA development. - Shareholders will vote on March 17, 2026, to rebrand the company as Thalia Therapeutics, marking its complete transition to a therapeutic biotechnology company. - Dr. Solomon brings over 30 years of biotechnology experience, including leading Zealand Pharma through its IPO and the global approval of Lixisenatide for type 2 diabetes.
- Zealand Pharma announced positive Phase 1a single ascending dose results for ZP9830, a potent and selective Kv1.3 channel blocker designed to treat immune-mediated inflammatory diseases. - The first-in-human trial demonstrated favorable safety and tolerability with no serious adverse events, dose-limiting safety findings, or clinically relevant safety concerns observed across all dose levels. - ZP9830 exhibited dose-proportional pharmacokinetics with very high bioavailability and showed robust, dose-dependent pharmacodynamic activity consistent with Kv1.3 target engagement. - The development program is progressing as planned, with Phase 1a multiple ascending dose data and Phase 1b/2a initiation expected in the second half of 2026.
- Boehringer Ingelheim has discontinued its inhaled gene therapy BI 3720931 for cystic fibrosis after the phase 1/2 Lenticlair 1 trial failed to generate efficacy data supporting further development. - The German pharmaceutical company is investing €25 billion over five years in R&D, driven by strong sales from Jardiance which increased 28% to €3.9 billion in 2021. - Despite the cystic fibrosis setback, Boehringer continues advancing multiple late-stage programs including zongertinib for lung cancer and nerandomilast for pulmonary fibrosis. - The company expects more than ten late-stage trials to read out within 12 to 18 months as its pipeline enters a more mature phase.
- Roche has entered into a patent licensing agreement with Structure Therapeutics subsidiary Gasherbrum Bio to secure rights for its investigational obesity pill CT-996, paying $100 million upfront plus low-single-digit royalties on net sales. - The December 30, 2025 agreement grants Roche non-exclusive rights to manufacture, use, and sell products containing CT-996 while addressing potential patent infringement concerns identified through IP landscape analysis. - Analysts view the deal as validation of Structure's intellectual property portfolio in GLP-1 receptor agonist small molecules, though it represents incremental rather than transformational value for the biotech. - The licensing agreement aligns with Roche's broader obesity strategy, following its $2.7 billion acquisition of Carmot Therapeutics in 2023 and $5.3 billion partnership with Zealand Pharma in 2024.
- Zealand Pharma announced its Metabolic Frontier 2030 strategy targeting five launches and more than ten clinical pipeline programs by 2030, positioning itself as a leader in obesity and metabolic health. - The company entered a multi-program strategic collaboration with OTR Therapeutics worth up to $2.5 billion to develop oral small-molecule therapeutics for metabolic diseases. - Zealand Pharma will establish a new research site in Boston combining its 25-year peptide expertise with AI-driven drug discovery and advanced automation. - The company expects catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026.
- Zealand Pharma has paused development of dapiglutide, a GLP-1/GLP-2 dual agonist obesity drug candidate, to focus resources on more differentiated programs in the increasingly competitive weight-loss market. - The decision reflects strategic portfolio management as the company prioritizes survodutide and petrelintide, two obesity assets with partnership backing from Boehringer Ingelheim and Roche respectively. - Dapiglutide showed 11.6% weight loss after 28 weeks in Phase Ib trials, but demonstrating its anti-inflammatory effects would require long and complex studies in the crowded GLP-1 space. - Zealand expects Phase III data for survodutide in first half 2026 and Phase II results for petrelintide throughout 2026, with late-stage development planned for the latter half of next year.
